Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting

NEW HAVEN, Conn. , May 08, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced a significant corporate presence at the upcoming Making a


Leave a Reply

Your email address will not be published.